Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Adagio Medical Holdings ( (ADGM) ) has shared an update.
On March 11, 2025, John Dahldorf, CFO of Adagio Medical Holdings, announced his resignation effective March 21, 2025. His departure was not due to any disagreements with the company, and a search for his replacement is underway. The company is advancing its focus on ventricular tachycardia solutions, with participation in the 2025 European Heart Rhythm Association Annual Meeting and progress in its FULCRUM-VT IDE Pivotal Study, which is over 40% enrolled. CEO Todd Usen expressed confidence in the company’s ability to meet its goals and thanked Dahldorf for his contributions.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an early commercial stage medical device company based in Laguna Hills, California, specializing in the development of proprietary Ultra-Low Temperature Cryoablation technology for treating cardiac arrhythmias, with a focus on ventricular tachycardia.
YTD Price Performance: -7.69%
Average Trading Volume: 531,456
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.61M
For detailed information about ADGM stock, go to TipRanks’ Stock Analysis page.